111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血小板指标和载脂蛋白 A1 作为局部晚期食管鳞状细胞癌新辅助免疫化疗预测标志物的回顾性研究
Authors Zeng T , Liu YC, Wang XH, Yan J, Li SB, Deng D, Xing S
Received 2 October 2025
Accepted for publication 16 November 2025
Published 3 December 2025 Volume 2025:18 Pages 16967—16980
DOI https://doi.org/10.2147/JIR.S567945
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Junhao Wang
Tao Zeng,1,2,* Yue-chang Liu,1,2,* Xiang-hui Wang,1,2,* Jun Yan,3 Shi-bing Li,1,2 Danning Deng,1,2 Shan Xing4
1Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510655, People’s Republic of China; 2Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People’s Republic of China; 3Department of Clinical Laboratory, Guangdong Medical University, Zhanjiang, 524023, People’s Republic of China; 4Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Danning Deng, Department of Clinical Laboratory, the Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Erheng Road of Yuancun, Tianhe District, Guangzhou, 510655, People’s Republic of China, Email dengdn@mail.sysu.edu.cn Shan Xing, Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China, Email Xingshan@sysucc.org.cn
Purpose: To evaluate the predictive value of baseline and preoperative blood parameters for treatment efficacy and prognosis in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoimmunotherapy (nCIT) followed by radical surgery.
Patients and Methods: This retrospective study analyzed clinical data from patients with LA-ESCC patients treated with nCIT followed by surgery (October 2019-November 2024). Patients were categorized based on pathological response (pathological complete response [pCR] and major pathological response [MPR]). Univariate and multivariate analyses identified factors associated with pCR and MPR. Cox regression and Kaplan-Meier methods were used to evaluate overall survival (OS) and disease-free survival (DFS). Nomograms and Receiver Operating Characteristic (ROC) curves were created for prognostic prediction.
Results: Among 236 patients, the pCR rate was 31.8%, and the MPR rate was 51.7%. pCR was associated with improved DFS (Hazard Ratio [HR] = 0.27, 95% CI: 0.16– 0.43, p < 0.0001) but not OS (p = 0.058). MPR was significantly correlated with both DFS (HR=0.27, 95% CI: 0.17– 0.44, p < 0.0001) and OS (HR=0.38, 95% CI: 0.21– 0.71, p = 0.0023). Identified predictors of treatment response included baseline and preoperative platelet indices (mean platelet volume [MPV], platelet distribution width [PDW], platelet-large cell ratio [P-LCR]) for both pCR and MPR, along with preoperative Apolipoprotein A1 (ApoA1) specifically for MPR (all identified as independent predictors on univariate and multivariate analysis, p < 0.05), reflecting their role in modulating the inflammatory response. A predictive model combining MPV (HR = 0.86, 95% CI: 0.61– 1.22) and ApoA1 (HR = 0.24, 95% CI: 0.07– 0.81) demonstrated good accuracy in forecasting DFS (30 months: AUC = 0.71, 95% CI: 0.60– 0.81).
Conclusion: Baseline and preoperative blood parameters (MPV, PDW, P-LCR) and preoperative ApoA1 are valuable predictors of treatment response and prognosis in LA-ESCC. Nomograms incorporating these markers offer reliable prognostic insights for DFS.
Keywords: esophageal squamous cell carcinoma, neoadjuvant therapy, pathological complete response, prognosis, inflammation, biomarkers
1Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510655, People’s Republic of China; 2Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People’s Republic of China; 3Department of Clinical Laboratory, Guangdong Medical University, Zhanjiang, 524023, People’s Republic of China; 4Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Danning Deng, Department of Clinical Laboratory, the Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Erheng Road of Yuancun, Tianhe District, Guangzhou, 510655, People’s Republic of China, Email dengdn@mail.sysu.edu.cn Shan Xing, Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People’s Republic of China, Email Xingshan@sysucc.org.cn
Purpose: To evaluate the predictive value of baseline and preoperative blood parameters for treatment efficacy and prognosis in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoimmunotherapy (nCIT) followed by radical surgery.
Patients and Methods: This retrospective study analyzed clinical data from patients with LA-ESCC patients treated with nCIT followed by surgery (October 2019-November 2024). Patients were categorized based on pathological response (pathological complete response [pCR] and major pathological response [MPR]). Univariate and multivariate analyses identified factors associated with pCR and MPR. Cox regression and Kaplan-Meier methods were used to evaluate overall survival (OS) and disease-free survival (DFS). Nomograms and Receiver Operating Characteristic (ROC) curves were created for prognostic prediction.
Results: Among 236 patients, the pCR rate was 31.8%, and the MPR rate was 51.7%. pCR was associated with improved DFS (Hazard Ratio [HR] = 0.27, 95% CI: 0.16– 0.43, p < 0.0001) but not OS (p = 0.058). MPR was significantly correlated with both DFS (HR=0.27, 95% CI: 0.17– 0.44, p < 0.0001) and OS (HR=0.38, 95% CI: 0.21– 0.71, p = 0.0023). Identified predictors of treatment response included baseline and preoperative platelet indices (mean platelet volume [MPV], platelet distribution width [PDW], platelet-large cell ratio [P-LCR]) for both pCR and MPR, along with preoperative Apolipoprotein A1 (ApoA1) specifically for MPR (all identified as independent predictors on univariate and multivariate analysis, p < 0.05), reflecting their role in modulating the inflammatory response. A predictive model combining MPV (HR = 0.86, 95% CI: 0.61– 1.22) and ApoA1 (HR = 0.24, 95% CI: 0.07– 0.81) demonstrated good accuracy in forecasting DFS (30 months: AUC = 0.71, 95% CI: 0.60– 0.81).
Conclusion: Baseline and preoperative blood parameters (MPV, PDW, P-LCR) and preoperative ApoA1 are valuable predictors of treatment response and prognosis in LA-ESCC. Nomograms incorporating these markers offer reliable prognostic insights for DFS.
Keywords: esophageal squamous cell carcinoma, neoadjuvant therapy, pathological complete response, prognosis, inflammation, biomarkers